Queen Mary University of London | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity	Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder	Recruiting	Phase 3	2026-10-08		NCT07037433
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial	Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder	Active, not recruiting	Phase 3	2026-02-27		NCT05581303
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	cardiovascular disorder, inflammatory disease	Recruiting	Not stated	2026-02-05		NCT04698291
The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders	Dyskinesias, Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dystonic disorder, eye disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, synucleinopathy, tauopathy, vascular parkinsonism	Recruiting	Not applicable	2024-11-21		NCT06174948